{"entity":{"id":"thierry-andre","kind":"person","name":"Thierry André","aka":[],"tldr":"Led MOSAIC, which made FOLFOX the adjuvant standard, and KEYNOTE-177, which made pembrolizumab first-line for MSI-high colon cancer.","summary":"Thierry André (Hôpital Saint-Antoine, Paris) was principal investigator of MOSAIC, the trial that established oxaliplatin-based adjuvant chemotherapy for stage III colon cancer, and two decades later of KEYNOTE-177, which showed pembrolizumab doubles progression-free survival versus chemotherapy in MSI-high metastatic colorectal cancer. He also led CheckMate 8HW (nivolumab plus ipilimumab) and the IDEA collaboration on three versus six months of adjuvant therapy. He remains a leading GERCOR investigator.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Andre%20T%5BAuthor%5D%20colorectal%20pembrolizumab%20OR%20MOSAIC"}],"tags":["colorectal","immunotherapy","adjuvant"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":["pd1","ctla4"],"drugs":["pembrolizumab","nivolumab","ipilimumab"],"companies":[],"institutions":["iuc-aphp-sorbonne"],"pathways":[],"terms":[],"trials":["keynote-177","checkmate-8hw"],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-177-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Sorbonne University; Head of Medical Oncology, Hôpital Saint-Antoine, Paris","institutionId":"iuc-aphp-sorbonne","specialisms":["Colorectal cancer","Adjuvant chemotherapy","MSI-high immunotherapy","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Andre%20T%5BAuthor%5D%20colorectal%20pembrolizumab%20OR%20MOSAIC"}],"papers":[{"title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)","journal":"NEJM","year":2004,"doi":"10.1056/NEJMoa032709"},{"title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer (KEYNOTE-177)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2017699"},{"title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2402141"}]},"route":"/people/thierry-andre/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"iuc-aphp-sorbonne","kind":"institution","name":"Institut Universitaire de Cancérologie AP-HP Sorbonne Université","route":"/institutions/iuc-aphp-sorbonne/"}],"trial":[{"id":"checkmate-8hw","kind":"trial","name":"CheckMate 8HW","route":"/trials/checkmate-8hw/"},{"id":"keynote-177","kind":"trial","name":"KEYNOTE-177","route":"/trials/keynote-177/"}],"paper":[{"id":"paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018","kind":"paper","name":"Duration of adjuvant chemotherapy for stage III colon cancer (the IDEA collaboration)","route":"/key-papers/paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018/"},{"id":"paper-keynote-177-nejm-2020","kind":"paper","name":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","route":"/key-papers/paper-keynote-177-nejm-2020/"},{"id":"paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017","kind":"paper","name":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142)","route":"/key-papers/paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017/"},{"id":"paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024","kind":"paper","name":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)","route":"/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/"},{"id":"paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004","kind":"paper","name":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)","route":"/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/"},{"id":"paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER)","route":"/key-papers/paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023/"}],"roadmap":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"}]}}